Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    Duloxetine, SSRIs Produce Similar Rates of Sexual Dysfunction in Patients With Depression: Presented at WCBP - (DGDispatch)
    TopAbstracts in Depression 07/01/2009 - (DGNews)
    Desvenlafaxine Reduces Anxiety Associated With Major Depressive Disorder: Presented at WCBP - (DGDispatch)
    Desvenlafaxine Is Effective for Major Depressive Disorder: Presented at WCBP - (DGDispatch)
    Armodafinil Improves Excessive Sleepiness Associated With Treated Obstructive Sleep Apnoea in Patients With Depression: Presented at ENS - (DGDispatch)

    News archive

     Recent webcasts/CME - Depression
      Treatment-Resistant Depression -- Part III: Switching Antidepressants vs. Conventional Augmentation Strategies
      On the Front Line of Major Depressive Disorder and Comorbidities: Managed Care and the Primary Care Physician
      Treatment-Resistant Depression -- Part II: Augmentation Strategies
      Treatment-Resistant Depression -- Part I: Introduction and Clinical Presentations
      Enhancing Treatment for Patients with Comorbid Depression, Diabetes and Heart Disease

      Webcasts/CME archive

       Recent cases - Depression
        Creutzfeldt-Jacob Disease Presenting as Severe Depression: A Case Report
        Sexual Dysfunction in a Young Mother
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
        Affective Psychosis, Hashimoto's Thyroiditis, and Brain Perfusion Abnormalities: Case Report

        Cases archive
          




        my personal edition > depression > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Sertraline Is Effective in Treatment of Depression of Older Adults

        A DGReview of :"An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression"
        American Journal of Psychiatry

        07/21/2003
        By Martha Kerr


        The selective serotonin reuptake inhibitor sertraline was well tolerated and showed efficacy in the treatment of older adults with depression, according to findings from an 8-week, multicentre trial.

        Study authors, led by Dr. Lon A. Schneider, University of Southern California in Los Angeles, believe this to be the first placebo-controlled trial of sertraline for older adults with depression.

        The study randomised 747 outpatients aged 60 and older to sertraline of placebo. All patients had a diagnosis of major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV), and a Hamilton Depression (HAM-D) Rating Scale score of 18 or greater.

        A total of 371 patients received sertraline, starting at 50 mg or 100 mg daily, and 376 patients received placebo.

        HAM-D scores decreased a mean of 7.4 points in the sertraline group and 6.6 points in the placebo group. Clinical response, defined by the Clinical Global Impression scale, occurred in 45% of sertraline-treated patients and in 35% of placebo patients, a difference that was statistically significant.

        Discontinuation of treatment due to adverse effects occurred in 8% of sertraline-treated patients and in 2% of placebo patients.

        Dr. Schneider and associates say that the active treatment effect was greater toward the end of the 8-week trial, while improvement levelled off at about 6 weeks in the placebo group. "It may be that treatment of late-life depression, especially in patients with substantial medical co-morbidity, has a longer response latency than is observed in younger adults," they write.

        The investigators speculate, "improvement in the sertraline group, and a greater drug-placebo difference, may have occurred if the trial had been longer."
        Am J Psychiatry 2003;160:7:1277-1285. "An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send